Atea Pharmaceuticals Inc stock is traded at $4.24, with a volume of 11,257. It is up +0.36% in the last 24 hours and down -16.47% over the past month. Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Previous Close:
$4.22
Open:
$4.21
24h Volume:
11,257
Relative Volume:
0.04
Market Cap:
$339.67M
Revenue:
$351.37M
Net Income/Loss:
-$169.52M
P/E Ratio:
-
EPS:
-$2.12
Net Cash Flow:
-$147.86M
1W Performance:
+3.04%
1M Performance:
-16.47%
6M Performance:
-25.04%
1Y Performance:
+30.31%
1-Day Range:
$4.12$4.29
1-Week Range:
$3.95$4.50
52-Week Range:
$2.87$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(857) 284-8891Address
225 FRANKLIN STREET, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS